- Vascular Biogenics Ltd and Notable Labs Inc M&A Call TranscriptFeb 23, 2023
- Q1 2022 Vascular Biogenics Ltd Earnings Call TranscriptMay 17, 2022Earnings
- Vascular Biogenics Ltd KOL Event on Ovarian Cancer TranscriptApr 11, 2022
- Vascular Biogenics Ltd at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) - Fireside Chat TranscriptFeb 10, 2022
- Q3 2021 Vascular Biogenics Ltd Earnings Call TranscriptNov 15, 2021Earnings
- Q2 2021 Vascular Biogenics Ltd Earnings Call TranscriptAug 16, 2021Earnings
- Q1 2021 Vascular Biogenics Ltd Earnings Call TranscriptMay 11, 2021Earnings
- Vascular Biogenics Ltd Virtual R&D Day & Corporate Update TranscriptApr 06, 2021
- Q4 2020 Vascular Biogenics Ltd Earnings Call TranscriptMar 25, 2021Earnings
- Q3 2020 Vascular Biogenics Ltd Earnings Call TranscriptNov 16, 2020Earnings
- Q2 2020 Vascular Biogenics Ltd Earnings Call TranscriptAug 13, 2020Earnings
- Q4 2019 Vascular Biogenics Ltd Earnings Call TranscriptMar 19, 2020Earnings
- Q1 2019 Vascular Biogenics Ltd Earnings Call TranscriptMay 15, 2019Earnings
- Q4 2018 Vascular Biogenics Ltd Earnings Call TranscriptMar 28, 2019Earnings
Q3 2021 Vascular Biogenics Ltd Earnings Call Transcript
Good morning, and welcome to VBL Therapeutics Third Quarter 2021 Earnings Call. (Operator Instructions) Please note that this conference is being recorded. (Operator Instructions)
I would now like to turn the conference over to Erez from the VBL team. Please go ahead.
Thank you, operator. Good morning, everyone, and thank you for joining the VBL Therapeutics Third Quarter 2021 Financial Results and Corporate Update Call. Joining me on the call is Professor Dror Harats, Chief Executive Officer; and Sam Backenroth, Chief Financial Officer. The press release for the company's financial results was issued earlier this morning and is available on the Investor Relations page of VBL's website at ir.vblrx.com.
Before turning the call over to Dror and Sam, I would like to remind everyone that during this conference call, forward-looking statements made by management are intended to fall within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, and Section
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)